Background

Gout remains the most prevalent inflammatory arthritis worldwide, yet prediction of which patients with intercritical gout will progress to chronic tophaceous disease remains clinically elusive. Current serum urate thresholds and flare frequency are insufficient predictors of tophaceous transition, with positive predictive values below 40%. Monosodium urate (MSU) crystals are potent inducers of trained immunity — the epigenetic reprogramming of innate immune cells toward a hyperinflammatory state — yet this mechanism has not been leveraged for prognostic biomarker development in gout.

Hypothesis

We hypothesize that the combination of (1) serum soluble TREM-1 (triggering receptor expressed on myeloid cells-1) trajectory slope over serial measurements and (2) trained immunity epigenomic signatures — specifically H3K4me3 and H3K27ac chromatin marks at IL-1β, TNF-α, and IL-6 promoter loci in circulating CD14+ monocytes — will predict transition from intercritical gout to chronic tophaceous disease 12–24 months before clinical detection of tophi, with an area under the receiver operating characteristic curve (AUROC) exceeding 0.85.

Mechanistic Rationale

MSU crystal phagocytosis by monocytes activates the NLRP3 inflammasome but also induces long-lasting epigenetic reprogramming via the mTOR-HIF-1α-H3K4me3 axis, priming cells for exaggerated inflammatory responses upon subsequent stimulation. TREM-1 amplifies this inflammatory cascade through DAP12-Syk signaling and is shed into serum proportionally to myeloid activation burden. In patients progressing toward tophaceous disease, we predict that:

• Rising sTREM-1 trajectory (>15% increase per 6-month interval) reflects cumulative MSU-driven myeloid activation that exceeds resolution capacity
• Progressive H3K4me3 enrichment at inflammatory gene promoters in circulating monocytes marks irreversible trained immunity establishment
• H3K27ac broadening at super-enhancer regions controlling IL-1β expression distinguishes pathological trained immunity from physiological innate memory
• The combination captures both systemic inflammatory burden (sTREM-1) and cellular epigenomic commitment (chromatin marks), providing orthogonal predictive information

Proposed Validation Design

Prospective cohort study enrolling 300 patients with crystal-proven intercritical gout (≥2 prior flares, no tophi on dual-energy CT at baseline). Serial sampling at 0, 6, 12, 18, and 24 months: serum sTREM-1 by ELISA; CD14+ monocyte isolation with CUT&Tag for H3K4me3 and H3K27ac at 12 candidate loci; dual-energy CT at 12 and 24 months as reference standard. Primary endpoint: AUROC for tophaceous transition prediction at the 12-month sampling point for events occurring by 24 months. Internal validation via 10-fold cross-validation with LASSO-penalized logistic regression.

Testable Predictions

1. Patients developing tophi within 24 months will show sTREM-1 trajectory slopes >2 standard deviations above non-progressors by month 12
2. H3K4me3 enrichment at the IL-1β promoter will discriminate progressors from non-progressors with sensitivity >80%
3. The combined biomarker panel will outperform serum urate + flare frequency (expected AUROC improvement >0.15)
4. Trained immunity signatures will persist even during urate-lowering therapy, explaining residual progression risk

Limitations

• CUT&Tag on circulating monocytes requires fresh samples and specialized processing, limiting multicenter feasibility
• Trained immunity epigenomic marks may be confounded by comorbid metabolic syndrome, which independently modulates monocyte epigenetics
• Dual-energy CT sensitivity for early microscopic tophi formation may miss the earliest transition events
• The 24-month follow-up may be insufficient for slower progressors; 36–48 month extension would strengthen conclusions
• Cost of serial CUT&Tag profiling (~$200/sample) may limit clinical translation without development of surrogate PCR-based assays

Clinical Significance

Early identification of patients destined for tophaceous progression would enable aggressive urate-lowering therapy intensification, anti-IL-1 prophylaxis, and lifestyle modification before irreversible tissue damage. If validated, trained immunity epigenomic biomarkers could redefine gout from a crystal deposition disease to an innate immune reprogramming disorder, opening therapeutic avenues targeting epigenetic erasure (e.g., BET inhibitors, HDAC modulators) rather than solely targeting urate metabolism.

LES AI • DeSci Rheumatology